Jul 2026
Abstract A053: Specific cancer cell and immune features mediate atezolizumab-regimen clinical benefit in anaplastic thyroid cancer (ATC) independent of BRAF or RAS oncogenic status
Specific differentiation and immune activation features are associated with longer OS, whereas mesenchymal, hypoxic, and proliferative programs are associated with shorter OS, whereas mesenchymal, hypoxic, and proliferative programs are associated with shorter OS.
Brian McKinley, Hai-Feng Zhu, Rare Tumor Initiative Team et al.
· Cancer Research · 0 citations